Dr. Muro on Pembrolizumab for Gastric Cancer

Name: Dr. Muro on Pembrolizumab for Gastric Cancer
Uploaded: 2015-01-19T15:40:44.000Z
Description: Kei Muro, MD, of the Aichi Cancer Center Hospital in Nagoya, Japan, discusses updated findings from the KEYNOTE-012 study, which looked at pembrolizumab for the treatment if several types of cancer.

January 19, 2015

Kei Muro, MD

Video

Conference|Gastrointestinal Cancers Symposium (ASCO GI)

Kei Muro, MD, of the Aichi Cancer Center Hospital in Nagoya, Japan, discusses updated findings from the KEYNOTE-012 study, which looked at pembrolizumab for the treatment if several types of cancer.

Kei Muro, MD, of the Aichi Cancer Center Hospital in Nagoya, Japan, discusses updated findings from the KEYNOTE-012 study, which looked at pembrolizumab for the treatment of several types of cancer.

Muro recently presented on the gastric cancer cohort of KEYNOTE-012, which included 39 patients whose tumors expressed PD-L1. The study included 19 Asian and 22 non-Asian patients.

The objective response rate (ORR) was 22.2% and the toxicity profile was very manageable. Median progression-free survival (PFS) was 1.9 months and at 6 months, the PFS rate was 24%, and the overall survival (OS) rate was 69%.